Platelet activation and coronary stent implantation: Effect of antithrombotic therapy

Circulation

Volumn 94, Issue 3, 1996, Pages 279-285

  Gawaz, Meinrad ^a   Neumann, Franz Josef ^a   Ott, Ilka ^a   May, Andreas ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

angioplasty; glycoproteins; platelets; stents; ticlopidine

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; FIBRINOGEN; FIBRINOGEN RECEPTOR; GLYCOPROTEIN; HEPARIN; IOPAMIDOL; MONOCLONAL ANTIBODY; PADGEM PROTEIN; PHENPROCOUMON; TICLOPIDINE;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GASTROINTESTINAL HEMORRHAGE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTRAARTERIAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; ORAL DRUG ADMINISTRATION; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; STENT; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOSIS;

EID: 0029814641     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.3.279     Document Type: Article

References (39)

1. Herrmann HC, Buchbinder M, Clemen MW, Fischman D, Goldberg S, Leon MB, Schatz RA, Tierstein P, Walker CM, Hirshfeld JW Jr. Emergent use of balloon-expandable coronary artery stenting for failed percutaneous transluminal coronary angioplasty. Circulation. 1992;86:812-819.
2. Kastrati A, Schömig A, Dietz R, Neumann FJ, Richardt G. Time course of restenosis during the first year after emergency coronary stenting. Circulation. 1993;87:1498-1505.
3. Schömig A, Kastrati A, Dietz R, Rauch B, Neumann FJ, Katus HH, Busch U. Emergency coronary stenting for dissection during percutaneous transluminal coronary angioplasty: angiographic follow-up after stenting and after repeat angioplasty of the stented segment. J Am Coll Cardiol 1994;23:1053-1060.
4. Roubin GS, Cannon AD, Agrawal SK, Macander PJ, Dean LS, Baxley WA, Breland J. Intracoronary stenting for acute and threatened closure complicating percutaneous transluminal coronary angioplasty. Circulation. 1992;85:916-927.
5. Sigwart U, Urvan P, Golf S, Kaufmann U, Imbert C, Fischer A, Kappenberger L. Emergency stenting for acute occlusion after coronary balloon angioplasty. Circulation. 1988;78:1121-1127.
6. Schömig A, Kastrati A, Mudra H, Blasini R, Schühlen H, Klauss V, Richardt G, Neumann FJ. Four-year experience with Palmaz-Schatz stenting in coronary angioplasty complicated by dissection with threatened or present vessel closure. Circulation. 1994;90:2716-2724.
7. Serruys PW, de Jaegere P, Kiemeneij F, Macaya C, Rutsch W, Heyndrickx G, Emanuelsson H, Marco J, Legrand V, Materne P. A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med. 1994;331:489-495.
8. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496-501.
9. Schatz RA, Baim DS, Leon M, Ellis SG, Goldberg S, Hirshfeld JW, Cleman MW, Cabin HS, Walker C, Stagg J. Clinical experience with the Palmaz-Schatz coronary stent: initial results of a multicenter study. Circulation. 1991;83:148-161.
10. Brack MJ, Hubner PJ, Gershlick AH. Anticoagulation after intracoronary stent insertion. Br Heart J. 1994;72:171-173.
11. Schatz RA, Palmaz JC, Tio FO, Garcia F, Garcia O, Reuter SR. Balloon-expandable intracoronary stents in the adult dog. Circulation. 1987;76:450-457.
12. Topol EJ. Caveats about elective coronary stenting. N Engl J Med. 1994;331:539-541.
13. Gawaz M, Ott I, Neumann FJ. Surface expression of platelet membrane glycoproteins following coronary stenting: effect on subacute stent thrombosis? Circulation. 1994;90(suppl I):I-552. Abstract.
14. Tschoepe D, Schultheiß HP, Kolarov P, Schwippert B, Dannehl K, Nieuwenhuis HK, Kehrel B, Strauer B, Gries FA. Platelet membrane activation markers are predictive for increased risk of acute ischemic events after PTCA. Circulation. 1993;88:37-42.
15. Colombo A, Hall P, Nakamura S, Almagor Y, Maiello L, Martini G, Gaglione A, Goldberg SL, Tobis JM. Intracoronary stenting without anticoagulation accomplished with intravascular ultrasound guidance. Circulation. 1995;91:1676-1688.
16. Hall P, Colombo A, Nakamura S, Maiello L, Blengino S, Ferraro M, Martini G. A prospective study of Giantureo-Roubin coronary stent implantation without subsequent anticoagulation. Circulation. 1994;90(suppl I):I-124. Abstract.
17. Jordan C, Carvalho H, Fajadet J, Cassagneau B, Robert G, Marco J. Reduction of subacute thrombosis rate after coronary stenting during a new anticoagulant protocol. Circulation. 1994;90(suppl I):I-125. Abstract.
18. Gawaz MP, Mujais SK, Schmidt B, Gurland HJ. Platelet leukocyte aggregation during hemodialysis. Kidney Int. 1994;46:489-495.
19. Gawaz MP, Dobos G, Späth M, Mujais SK. Platelet membrane glycoprotein IIb-IIIa function is impaired in end-stage renal failure (ESRF). J Am Soc Nephrol. 1994;5:36-46.
20. Gawaz M, Fateh-Moghadam S, Pilz G, Gurland HJ, Werdan K. Platelet activation and interaction with leukocytes in patients with sepsis or multiple organ failure. Eur J Clin Invest. 1995;25:843-851.
21. Gawaz M, Neumann F-J, Ott I, Schießler A, Schömig A. Platelet function in acute myocardial infarction treated by direct angioplasty. Circulation. 1996;93:229-237.
22. Ginsberg MH, Frelinger AL, Lam SCT, Forsyth J, McMillan R, Plow EF, Shattil SJ. Analysis of platelet aggregation disorders based on flow cytometric analysis of platelet membrane glycoprotein IIb-IIIa with conformation specific monoclonal antibodies. Blood. 1990; 76:2017-2023.
23. McEver RP. The clinical significance of platelet membrane glycoproteins. Hematol Oncol Clin North Am. 1990;4:87-103.
24. Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb Haemost. 1991;65:467-473.
25. Scharf RE, Tomer A, Mrzec UM, Teirstein PS, Ruggeri ZM, Harker L. Activation of platelets in blood perfusing angioplasty-damaged coronary arteries: flow cytometric detection. Arterioscler Thromb. 1992;12:1475-1487.
26. Nurden AT, Macchi L, Bihour C, Durrieu C, Besse P, Nurden P. Markers of platelet activation in coronary hearts disease patients. Eur J Clin Invest. 1994;24:42-45.
27. Langford EJ, Brown AS, Wainwright RJ, deBelder AJ, Thomas MR, Smith REA, Radomski MW, Martin JF, Moncada S. Inhibition of platelet activity by S-nitrosoglutathione during coronary angioplasty. Lancet. 1994;344:1458-1460.
28. Neumann F-J, Gawaz M, Ott I, May A, Mössmer G, Schömig A. Prospective evaluation of hemostatic predictors of subacute stent thrombosis after coronary Palmaz-Schatz stenting. J Am Coll Cardiol 1996;27:15-21.
29. Gent M. A systematic overview of randomized trials of antiplatelet agents for the prevention of stroke, myocardial infarction, and vascular death. In: Hass K, Easton JD, eds. Ticlopidine, Platelets and Vascular Disease. New York, NY: Springer-Verlag; 1993:99-116.
30. Harker A, Bruno JJ. Ticlopidine's mechanism of action on human platelets. In: Hass K, Easton JD, eds. Ticlopidine, Platelets and Vascular Disease. New York, NY: Springer-Verlag; 1993:41-59.
31. Salzman EW, Rosenberg RD, Smith MH, Lindon JN, Favreau L. Effects of heparin and heparin fractions on platelet aggregation. J Clin Invest. 1980;65:65-73.
32. Landolfi R, DeCandia E, Rocca B, Ciabattoni G, Antinori A, Masetti R, Patrono C. Effects of unfractionated and low molecular weight heparins on platelet thromboxane biosynthesis 'in vivo.' Thromb Haemost. l994;72:942-946.
33. Plow EF, Ginsburg MH. Cellular adhesion: GPIIb-IIIa as a prototypic adhesion receptor. In: Coller BS, ed. Progress in Hemostasis and Thrombosis. Philadelphia, Pa: WB Saunders Co; 1989:117-156.
34. EPIC Inverstigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
35. Siess W. Molecular mechanisms of platelet activation. Physiol Rev. 1989;69:50-178.
36. Libby P, Schwartz D, Brogi E, Tanaka H, Clinton SK. A cascade model for restenosis: a special case of atherosclerosis progression. Circulation. 1992;86(suppl III):III-47-III-52.
37. Ernst E. The role of fibrinogen as a cardiovascular risk factor. Atherosclerosis. 1993;100;1-2.
38. Meade TW, Vickers MV, Thompson SG, Stirling Y, Haines AP, Miller GJ. Epidemiological characteristics of platelet aggregability. Br Med J. 1985;290:428-432.
39. Srivastra R, Srimal RC. Amplification of platelet response during acute inflammation in rats. Biochem Pharmacol. 1990;40:357-363.